Amantadine use in the French prospective NS-Park cohort.

Autor:	Fabbri M; Department of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC1436, Toulouse Parkinson Expert Centre, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), University of Toulouse 3, CHU of Toulouse, INSERM, Toulouse, France. margheritafabbrimd@gmail.com.; Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire-Faculté de Médecine, Toulouse, France. margheritafabbrimd@gmail.com.; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France. margheritafabbrimd@gmail.com., Rousseau V; Department of Clinical Pharmacology, Clinical Investigation Center CIC1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France., Corvol JC; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, Inserm, CNRS, Paris, France.; Department of Neurology, Assistance Publique Hôpitaux de Paris, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France., Sommet A; Department of Clinical Pharmacology, Clinical Investigation Center CIC1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France., Tubach F; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Unité de Recherche Clinique PSL-CFX, CIC-1901, F75013, Paris, France., De Rycke Y; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Unité de Recherche Clinique PSL-CFX, CIC-1901, F75013, Paris, France., Bertille N; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Unité de Recherche Clinique PSL-CFX, CIC-1901, F75013, Paris, France., Selvarasa Y; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, Inserm, CNRS, Paris, France.; Department of Neurology, Assistance Publique Hôpitaux de Paris, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France., Carvalho S; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, Inserm, CNRS, Paris, France.; Department of Neurology, Assistance Publique Hôpitaux de Paris, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France., Chaigneau V; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France., Brefel-Courbon C; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center CIC1436, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse NeuroImaging Center, Inserm, University of Toulouse 3, Toulouse, France., Ory-Magne F; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Service de Neurologie, Centre Hospitalier Universitaire, Toulouse, Université de Toulouse-Toulouse 3, INSERM, UMR1214 Toulouse NeuroImaging Centre 'TONIC,' Center of Excellence in Neurodegeneration (CoEN), NeuroToul, Parkinson Expert Center, Clinical Investigation Center CIC1436, Toulouse, France., Tessier S; Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire-Faculté de Médecine, Toulouse, France., Tir M; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Department of Neurology, University Hospital of Amiens, Amiens, France., Bereau M; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Department of Neurology, University Hospital of Besançon, Besançon, France., Meissner WG; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc, NS-Park/FCRIN Network, 33000, Bordeaux, France.; Univ. Bordeaux, CNRS, IMN, UMR5293, 33000, Bordeaux, France.; Dept. Medicine, University of Otago, Christchurch, New Zealand.; New Zealand Brain Research, Christchurch, New Zealand., Thiriez C; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Department of Neurology and Parkinson Expert Centre, Caen University-Hospital, Caen, France., Marques A; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Neurology Department, Université Clermont Auvergne, EA7280 NPsy-Sydo, Clermont-Ferrand University Hospital, Clermont-Ferrand, France., Remy P; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Centre Expert Parkinson, Neurologie, CHU Henri Mondor, AP-HP, Equipe NPI, IMRB INSERM Et Faculté de Santé, Université Paris-Est Créteil, Créteil, France., Schneider V; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Département de Neurologie, Centre Hospitalier Universitaire François Mitterrand, Université de Bourgogne, Dijon, France., Moro E; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Unité des Troubles du Movement, Service de Neurologie, Coordinatrice du Pole PRENELE, CHU de Grenoble, Assesseur Relations Internationales, Faculté de Médécine, Université Grenoble Alpes, President Elect, European Academy of Neurology, Grenoble, France., Defebvre L; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Movement Disorders Department, Lille University, Inserm 1172, Lille, France., Houeto JL; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Department of Neurology, Limoges University Hospital, Inserm, U1094, EpiMaCT-Epidemiology of Chronic Diseases in Tropical Zone, 87042, Limoges Cedex 01, France., Prange S; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Hospices Civils de Lyon, Pierre Wertheimer Neurological Hospital, Expert Parkinson Center, Lyon University, Bron, France.; Université Claude Bernard Lyon 1, Faculté de Médecine et de Maïeutique Lyon Sud Charles Mérieux, Oullins, France.; Marc Jeannerod Institute for Cognitive Neuroscience, CNRS, UMR 5229, Bron, France., Eusebio A; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Movement Disorders Unit, Neurology Department, University Hospital of Marseille, Marseille, France., Geny C; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; EuroMov, Univ. Montpellier, Montpellier, France.; Department of Neurology, CHRU Montpellier, Montpellier, France., Frismand S; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Service de Neurologie, Centre Expert Parkinson, Centre Mémoire de Ressources et de Recherche de Lorraine, Hôpital Central Nancy, Nancy, France., Damier P; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Service de Neurologie, CHU Nantes, INSERM, CIC, 1413, Nantes, France., Reuther CG; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Department of Neurology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France., Castelnovo G; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Department of Neurology, University Hospital of Nîmes, Nîmes, France., Benatru I; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Departement of Neurology, Poitiers University Hospital, INSERM, CHU de Poitiers, Centre d'Investigation Clinique CIC1402, Poitiers, France., De Maindreville AD; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Department of Neurology, Hôpital Maison Blanche, Reims, France., Drapier S; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Department of Neurology, Pontchaillou University Hospital, CIC INSERM 1414, Rennes, France., Maltête D; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.; Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, CEP Rouen, INSERM U1239, Mont-Saint-Aignan, France., Lagha-Boukbiza O; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.; Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France., Rascol O; Department of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC1436, Toulouse Parkinson Expert Centre, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), University of Toulouse 3, CHU of Toulouse, INSERM, Toulouse, France.; Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire-Faculté de Médecine, Toulouse, France.; French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.
Jazyk:	angličtina
Zdroj:	Journal of neural transmission (Vienna, Austria : 1996) [J Neural Transm (Vienna)] 2024 Jul; Vol. 131 (7), pp. 799-811. Date of Electronic Publication: 2024 Apr 05.
DOI:	10.1007/s00702-024-02772-4
Abstrakt:	Objective: To assess amantadine use and associated factors in the patients with Parkinson's disease (PD). Background: Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical practice to treat "levodopa-induced dyskinesia (LIDs). Its use varies according to countries and PD stages. The prospective NS-Park cohort collects features of PD patients followed by 26 French PD Expert Centres. Methods: Variables used for the analyses included demographics, motor and non-motor PD symptoms and motor complications [motor fluctuations (MFs), LIDs)], antiparkinsonian pharmacological classes and levodopa equivalent daily dose (LEDD). We evaluated: (i) prevalence of amantadine use and compared clinical features of amantadine users vs. non-users (cross-sectional analysis); (ii) factors associated with amantadine initiation (longitudinal analysis); (iii) amantadine effect on LIDs, MFs, apathy, impulse control disorders and freezing of gait (Fog) (longitudinal analysis). Results: Amantadine use prevalence was 12.6% (1,585/12,542, median dose = 200 mg). Amantadine users were significantly younger, with longer and more severe PD symptoms, greater LEDD and more frequent use of device-aided/surgical treatment. Factors independently associated with amantadine initiation were younger age, longer PD duration, more frequent LIDs, MFs and FoG, higher LEDD and better cognitive function. 9 of the 658 patients on amantadine had stopped it at the following visit, after 12-18 months (1.3%). New users of amantadine presented a higher improvement in LIDs and MF compared to amantadine never users. Conclusions: About 12% of PD patients within the French NS-Park cohort used amantadine, mostly those with younger age and more severe PD. Amantadine initiation was associated with a subsequent reduction in LIDs and MFs. (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink